Schering Corporation

Mark A Laughlin

Bernard R Neustadt

Anandan Palani

Brian Alexander McKittrick

John W Clader

Hubert B Josien

Stuart W McCombie

Michael W Miller

Jayaram R Tagat

Susan F Vice

Bahige M Baroudy

Ruo Steensma

Elizabeth M Smith

Eric J Gilbert

Marc A Labroli

Brian A Mckittrick

Huber B Josien

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein

Piperazine derivatives useful as CCR5 antagonists

Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.

Pegylated interferon alfa-CCR5 antagonist combination HIV therapy

Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b, in association with a therapeutically effective amount of a CCR5 antagonist or preferably further in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.

Piperidine derivatives useful as CCR5 antagonists

Growing community of inventors

Edison, NJ, United States of America

Mark A Laughlin